Skip to content

CagriSema vs Eloralintide

Updated 8 sources

Key differences

  1. 1Eloralintide is Lilly's amylin-only drug, selective for one amylin receptor. Alone at 9 mg it reached 20% weight loss at 48 weeks in phase 2.
  2. 2Lilly's answer to CagriSema pairs eloralintide with tirzepatide (EloraTZP), still in phase 2 to 3. No head-to-head trial exists.
  3. 3CagriSema pairs Novo's cagrilintide with semaglutide and has phase 3 data and a pending FDA filing; eloralintide is amylin only.
  4. 4Lilly's matching combination is EloraTZP (eloralintide plus tirzepatide), heading into phase 3. No head-to-head trial exists.

Side by side

Facts from each record, in the same words as their own pages.
CagriSema and Eloralintide side by side
CagriSemaEloralintide
Category
  • Weight loss, GLP-1
  • Weight loss
Evidence
  • Strong human trials
  • Some human trials
FDA status
  • In clinical trialsRegulatory
  • In clinical trialsRegulatory
WADA
  • Not confirmed
  • Not confirmed
Half-life
  • Cagrilintide component: 159 to 195 hours, peaking 24 to 72 hours after a dose (phase 1b, given with semaglutide).Clinical study
  • Semaglutide component: 145 to 165 hours, peaking 12 to 24 hours after a dose (same trial).Clinical study
  • About 13 to 15 days (310 to 366 hours) after single doses of 0.04 to 12 mg in healthy adults; levels peak 72 to 132 hours after a shot.Clinical study
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Forms
  • Vial (powder)
  • Vial (powder)
Reported doses
  • 0.16 to 4.5 mg (subcutaneous injection)
  • 0.5 to 12 mg (subcutaneous injection)
Most cited frequency
  • Once weekly, cagrilintide and semaglutide at the same mg (2.4 mg + 2.4 mg at maintenance)
  • Once weekly at 1, 3, 6 or 9 mg depending on arm
Vial sizes
  • 5 mg, 10 mg, 20 mgVendor guide
  • 10 mg, 30 mgVendor guide
Mixed vial keeps
  • Fridge at 2 to 8 °C, use within 30 days.Vendor guide
  • Fridge at 2 to 8 °C, protected from light.Vendor guide
Protocols on file
  • 6
  • 8

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

8 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory4

  1. openFDA Drugs@FDA query for cagrilintideFDA (openFDA) · checked Oct 24, 2026
  2. NCT05567796 (REDEFINE 1), phase 3, active not recruitingClinicalTrials.gov · checked Oct 24, 2026
  3. openFDA Drugs@FDA query for eloralintideFDA (openFDA) · checked Oct 24, 2026
  4. ENLIGHTEN-1 (NCT07321886): eloralintide in obesity or overweight without type 2 diabetes, phase 3, recruitingClinicalTrials.gov · checked Oct 24, 2026